MYGN
Myriad Genetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.19
−1.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 806.6M | 824.5M | 837.6M | 753.2M | 678.4M |
| Cost of Revenue | 251.4M | 247.9M | 252.2M | 236.2M | 202.0M |
| Gross Profit | 555.2M | 576.6M | 585.4M | 517.0M | 476.4M |
| Operating Expenses | |||||
| R&D Expense | 105.8M | 106.8M | 113.4M | 88.7M | 85.4M |
| SG&A Expense | 539.9M | 537.6M | 560.0M | 572.9M | 514.7M |
| General & Admin Expense | 243.5M | 256.8M | 275.9M | 283.7M | 247.9M |
| Selling & Marketing Expense | 296.4M | 280.8M | 284.1M | 289.2M | 266.8M |
| Other Expenses | 8.1M | — | — | — | — |
| Total Operating Expenses | 653.8M | 644.4M | 673.4M | 661.6M | 600.1M |
| Cost and Expenses | 905.2M | 892.3M | 925.6M | 897.8M | 802.1M |
| Operating Income (EBIT) | (98.6M) | (67.8M) | (88.0M) | (144.6M) | (123.7M) |
| Non-Operating | |||||
| Interest Income | 2.4M | 1.8M | 1.7M | 2.5M | 2.6M |
| Interest Expense | 16.4M | 10.5M | 2.8M | 2.9M | 3.2M |
| Net Interest Income | (14.0M) | (8.7M) | (1.1M) | (400.0K) | (600.0K) |
| Other Non-Op Income/Expense | (13.2M) | (327.3M) | (35.5M) | (117.6M) | (16.9M) |
| Non-Operating Income (excl Interest) | (3.2M) | 316.8M | 32.7M | 114.7M | 13.7M |
| EBT (Pre-Tax Income) | (111.8M) | (395.1M) | (123.5M) | (262.2M) | (140.6M) |
| Income Tax Expense | 800.0K | (29.2M) | 3.8M | 1.1M | (28.6M) |
| Bottom Line | |||||
| Net Income | (112.6M) | (365.9M) | (127.3M) | (263.3M) | (112.0M) |
| Earnings from Cont. Ops | (112.6M) | (365.9M) | (127.3M) | (263.3M) | (112.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (112.6M) | (365.9M) | (127.3M) | (263.3M) | (112.0M) |
| Per Share | |||||
| Basic EPS | ($1.19) | ($3.96) | ($1.41) | ($3.18) | ($1.39) |
| Diluted EPS | ($1.19) | ($3.96) | ($1.41) | ($3.18) | ($1.39) |
| Revenue Per Share | $8.51 | $8.84 | $9.25 | $9.10 | $8.42 |
| Shares | |||||
| Basic Shares Outstanding | 94.8M | 93.3M | 90.6M | 82.8M | 80.6M |
| Diluted Shares Outstanding | 94.8M | 93.3M | 90.6M | 82.8M | 80.6M |
| Profitability Metrics | |||||
| EBITDA | (45.2M) | (330.9M) | (59.5M) | (197.4M) | (84.7M) |
| D&A | 50.2M | 53.7M | 61.2M | 61.9M | 52.7M |
| EBIT | (95.4M) | (384.6M) | (120.7M) | (259.3M) | (137.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026